At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 64 enrolled
Drug / intervention
VRx-3996 and valganciclovircombination
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1b/2 Open-Label, Dose Escalation & Expansion Study of Orally Administered Viracta (VRx)-3996 & Valganciclovir in Subjects With Epstein-Barr Virus-Associated Lymphoid Malignancies
In Brief
A Phase 2 clinical trial evaluating VRx-3996 and valganciclovir for Epstein-Barr Virus-Associated Lymphoma and Lymphoproliferative Disorders. Completed, enrolled 64 participants across 28 sites in 2 countries.
Detailed Summary
A two part, Phase 1b/2 study to define a recommended Phase 2 dose of VRx-3996 in combination with valganciclovir (Phase 1b) designed to evaluate the efficacy of this combination in relapsed/refractory Epstein-Barr Virus Associated Lymphoma (EBV+ lymphomas).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesBrazil, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedJan 2018
Enrollment StartMar 2018
Primary CompletionApr 2023
Study CompletionMay 2023
TodayJul 2026
First PostedJan 12, 2018
Enrollment StartMar 29, 2018
Primary CompletionApr 1, 2023
Study CompletionMay 4, 2023
TodayJul 2, 2026
Enrollment to primary: 5.0 yearsPosted 8.5 years ago
Interventions
VRx-3996 and valganciclovircombination
second-generation histone deacetylase (HDAC) inhibitor, nanatinostat (previously referred to as either VRx-3996 or CHR-3396)